Weigao Group Medical Devices Co., Ltd. (stock code: 01066) surged nearly 5% during afternoon trading, maintaining a 4.55% gain at the time of writing to reach HK$6.21 per share. Trading volume hit HK$57.13 million as investors reacted to bullish forecasts.

Xiangcai Securities emphasized monitoring first-half performance guidance among medical consumables manufacturers. Following the implementation of national centralized procurement policies, companies securing favorable bidding positions are now capitalizing on diminished price-cut impacts to expand market share and boost sales volumes. This strategic positioning is expected to drive gradual earnings recovery, particularly among orthopedic consumables firms showing notable margin improvements since Q3 2024.

Nomura's research report projects Weigao's first-half sales will climb 6.2% year-on-year to RMB7.05 billion, with profits rising 8% to RMB1.2 billion. The brokerage attributes this resilience to robust growth in pharmaceutical packaging and orthopedic segments offsetting weaker performance in other medical consumables.

Looking ahead, Nomura anticipates accelerated momentum in the second half. Against a relatively low base in the same period last year, revenue could surge 15.8% to RMB7.5 billion while profits may leap 19.3% to RMB1.1 billion. This optimistic outlook reflects the company's strategic positioning in high-growth medical device categories and operational efficiency gains.